Additional file 1 of FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research—a systematic review and meta-analysis
Creators: name: S. Majothi
name: D. Adams
name: J. Loke
name: S. P. Stevens
name: K. Wheatley
name: J. S. Wilson
Publisher: name: figshare
Year: 2020
Subjects: Medicine
Pharmacology
Cancer
Science Policy

description: Additional file 1. MEDLINE (Ovid) search strategy for FLT3 inhibitors in patients with AML. Table S1. Ongoing trials meeting review inclusion criteria (ordered alphabetically by FLT3 inhibitor [column name: FLT3 inhibitor group details]. Table S2. Conference abstracts of trials meeting review inclusion criteria (ordered alphabetically by intervention)*. Table S3. Characteristics of included studies. Table S4. Treatment schedules for included trials. Table S5. Outcome definitions according to trials included in review. Table S6. Data sources and methods of calculation for all included outcomes. Table S7. Baseline and outcome data for FLT3-mutated patients from Rollig C, 2015. Table S8. Baseline and outcome data for FLT3-mutated patients from Serve H, 2013. Table S9. Baseline data for FLT3-mutated patients from Knapper S, 2017. Table S10. Outcome data for FLT3-mutated patients from Knapper S, 2017. Table S11. Baseline and outcome data for FLT3-mutated patients from Levis M, 2011. Table S12. Baseline and outcome data for FLT3-mutated patients from Stone RM, 2017. Table S13. Baseline and outcome data for FLT3-mutated patients from Perl AE, 2019. Table S14. Baseline data from FLT3-ITD-mutated patients from Cortes JE, 2019. Table S15. Outcome data for FLT3-mutated AML patients from Cortes JE, 2019. Fig. S1. Funnel plot of all eight included trials for overall survival. Fig. S2. Forest plot of event-free survival data (uncensored population), grouped by FLT3 inhibitor. Fig. S3. Forest plot of relapse-free survival data (uncensored population), grouped by FLT3 inhibitor. Fig. S4 Forest plot of complete remission data, grouped by FLT3 inhibitor. Fig. S5. Forest plot of overall response rate (CR + CRi/CRp) data, grouped by FLT3 inhibitor. Fig. S6. Forest plot of overall survival data, grouped by disease stage Fig. S7. Forest plot of event-free survival (calculated and reported data), grouped by disease stage. Fig. S8. Forest plot of overall survival, grouped by age categories. Fig. S9. Forest plot of event-free survival (calculated and reported data), grouped by age categories. Fig. S10. Forest plot of overall survival data (censored population), grouped by FLT3 inhibitor. Fig. S11. Forest plot of early death/mortality data. Fig. S12. Forest plot of vascular adverse events data. Fig. S13. Forest plot of dermatological adverse events data. Fig. S14. Forest plot of respiratory adverse events data. Fig. S15. Forest plot of liver/hepatobiliary adverse events data. Fig. S16. Forest plot of haematological adverse events data. Fig. S17. Forest plot of metabolism and nutritional disorders data. Fig. S18. Forest plot of gastrointestinal disorders data. Fig. S19. Forest plot of constitutional symptoms data. Fig. S20. Risk of bias graph of included trials. Fig. S21. Risk of bias summary of included trials.